YZ9

PFKFB3 inhibitor CAS# 6093-71-6

YZ9

Catalog No. BCC8001----Order now to get a substantial discount!

Product Name & Size Price Stock
YZ9: 5mg $58 In Stock
YZ9: 10mg Please Inquire In Stock
YZ9: 20mg Please Inquire Please Inquire
YZ9: 50mg Please Inquire Please Inquire
YZ9: 100mg Please Inquire Please Inquire
YZ9: 200mg Please Inquire Please Inquire
YZ9: 500mg Please Inquire Please Inquire
YZ9: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of YZ9

Number of papers citing our products

Chemical structure

YZ9

3D structure

Chemical Properties of YZ9

Cas No. 6093-71-6 SDF Download SDF
PubChem ID 5289613 Appearance Powder
Formula C12H10O5 M.Wt 234.2
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 50 mM in DMSO and to 20 mM in ethanol
Chemical Name ethyl 7-hydroxy-2-oxochromene-3-carboxylate
SMILES CCOC(=O)C1=CC2=C(C=C(C=C2)O)OC1=O
Standard InChIKey IETDBZQIWIJQJG-UHFFFAOYSA-N
Standard InChI InChI=1S/C12H10O5/c1-2-16-11(14)9-5-7-3-4-8(13)6-10(7)17-12(9)15/h3-6,13H,2H2,1H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of YZ9

DescriptionPFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor (IC50 = 0.183 μM). Also competitively inhibits F-6-P (Ki = 0.094 μM). Inhibits cell growth (GI50 = 2.7 μM) in a XTT-based in vitro toxicology assay.

YZ9 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

YZ9 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of YZ9

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.2699 mL 21.3493 mL 42.6985 mL 85.3971 mL 106.7464 mL
5 mM 0.854 mL 4.2699 mL 8.5397 mL 17.0794 mL 21.3493 mL
10 mM 0.427 mL 2.1349 mL 4.2699 mL 8.5397 mL 10.6746 mL
50 mM 0.0854 mL 0.427 mL 0.854 mL 1.7079 mL 2.1349 mL
100 mM 0.0427 mL 0.2135 mL 0.427 mL 0.854 mL 1.0675 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on YZ9

Effect of ceramic infrastructure on the failure behavior and stress distribution of fixed partial dentures.[Pubmed:25657090]

Dent Mater. 2015 Apr;31(4):413-22.

OBJECTIVES: The effect of the ceramic infrastructure (IS) on the failure behavior and stress distribution of fixed partial dentures (FPDs) was evaluated. METHODS: Twenty FPDs with a connector cross-section of 16 mm(2) were produced for each IS and veneered with porcelain: (YZ) Vita In-Ceram YZ/Vita VM9 porcelain; (IZ) Vita In-Ceram Zirconia/Vita VM7 porcelain; (AL) Vita In-Ceram AL/Vita VM7 porcelain. Two experimental conditions were evaluated (n = 10). For control specimens, load was applied in the center of the pontic at 0.5 mm/min until failure, using a universal testing machine, in 37 degrees C deionized water. For mechanical cycling (MC) specimens, FPDs were subjected to MC (2 Hz, 140 N, 10(6) cycles) and subsequently tested as described for the control group. For YZ, an extra group of 10 FPDs were built with a connector cross-section of 9 mm(2) and tested until failure. Fractography and FEA were performed. Data were analyzed by ANOVA and Tukey's test (alpha = 0.05). RESULTS: YZ16 showed the greatest fracture load mean value, followed by YZ16-MC. Specimens from groups YZ9, IZ16, IZ16-MC, AL16 and AL16-MC showed no significant difference for the fracture load. SIGNIFICANCE: The failure behavior and stress distribution of FPDs was influenced by the type of IS. AL and IZ FPDs showed similar fracture load values but different failure modes and stress distribution. YZ showed the best mechanical behavior and may be considered the material of choice to produce posterior FPDs as it was possible to obtain a good mechanical performance even with a smaller connector dimension (9 mm(2)).

Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect.[Pubmed:21957443]

PLoS One. 2011;6(9):e24179.

Cancer cells adopt glycolysis as the major source of metabolic energy production for fast cell growth. The HIF-1-induced PFKFB3 plays a key role in this adaptation by elevating the concentration of Fru-2,6-BP, the most potent glycolysis stimulator. As this metabolic conversion has been suggested to be a hallmark of cancer, PFKFB3 has emerged as a novel target for cancer chemotherapy. Here, we report that a small molecular inhibitor, N4A, was identified as an initial lead compound for PFKFB3 inhibitor with therapeutic potential. In an attempt to improve its potency, we determined the crystal structure of the PFKFB3*N4A complex to 2.4 A resolution and, exploiting the resulting molecular information, attained the more potent YN1. When tested on cultured cancer cells, both N4A and YN1 inhibited PFKFB3, suppressing the Fru-2,6-BP level, which in turn suppressed glycolysis and, ultimately, led to cell death. This study validates PFKFB3 as a target for new cancer therapies and provides a framework for future development efforts.

Keywords:

YZ9,6093-71-6,Natural Products,Others, buy YZ9 , YZ9 supplier , purchase YZ9 , YZ9 cost , YZ9 manufacturer , order YZ9 , high purity YZ9

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: